Drug intelligence / Profile preview

VRT002-D

Development stage: Preclinical
Lead developer: Venus Remedies
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

VRT002-D is a preclinical-stage oncology candidate developed by Venus Remedies using its proprietary Drug-Protein-Polymer-Conjugate (DPPC) platform technology. The DPPC platform is a triple-conjugate system designed for targeted drug delivery, comprising a protein moiety that selectively binds to a target organ or tumor site, a polymer moiety covalently linked to the protein, and an active drug payload. This targeted approach aims to increase the concentration and retention of the active drug at the tumor site while minimizing uptake by normal cells, thereby reducing systemic toxicity and side effects. VRT002-D is currently in the formulation and development (F&D) stage of preclinical research.

Other names: Anti Cancer Target Delivery Service VRT002-D

Beyond the preview

Go deeper on VRT002-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRT002-D.